What are the two consensus treatments for Stage B2 MMVR?

• A. Pimobendan and mild sodium restriction diet
• B. Pimobendan and lasix
• C. ACE inhibitors and diuretics
• D. Beta blockers

Answer: (A)

Stage B2 MMVR describes dogs that have myxomatous mitral valve disease with cardiac remodeling but are not yet in congestive heart failure. The goal in this stage is to slow progression and delay the onset of CHF. The two consensus treatments for this stage are pimobendan and a mild sodium-restricted diet. Pimobendan acts as an inodilator, improving contractility and causing vasodilation, which lowers left heart pressures and reduces wall stress, helping to slow remodeling and extend the time before heart failure occurs (evidence from trials supports longer time to CHF with early pimobendan). A mild sodium restriction diet helps limit fluid retention and volume overload, supporting the same goal of reducing cardiac stress. Other choices, like diuretics or certain heart medications, are generally reserved for when CHF develops or have not shown consistent benefit in delaying progression for asymptomatic Stage B2 dogs, so they aren’t part of the standard consensus management for this stage.